Publication details
Diagnostika a léčba BCR/ABL-negativních myeloproliferativních onemocnění-principy a východiska doporučení CZEMP
| Title in English | Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases – principles and rationale of CZEMP recommendations |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | Ph- myeloproliferative disease; essential thrombocythemia; polycythaemia vera; primary myelofibrosis; diagnosis; risk factors; treatment algorithm; hydroxyurea; anagrelide; hematopoietic stem cell transplantation |
| Description | In 2009, the recommendations of the Czech Collaborative Group for Ph- Myeloproliferative Diseases (CZEMP) for diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases (MPD), i.e. essential thrombocythemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF) were updated and extended. The present article gives the rationale of the recommendations in full detail. The CZEMP diagnostic criteria for ET and PMF are based on histopathological (HP) findings, which must unconditionally be in line with the given clinical and laboratory characteristics of ET or of a certain stage of PMF, respectively. The platelet count is not decisive for diagnosis. In cases lacking an adequately taken and read HP finding, the Polycythemia Vera Study Group (PVSG) criteria are recommended. |